Review



matrix m1 adjuvant  (Novavax Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Novavax Inc matrix m1 adjuvant
    Matrix M1 Adjuvant, supplied by Novavax Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/matrix+m1+adjuvant/adjuvant+m+matrix/pm41600941-63-0-6
    Average 86 stars, based on 1 article reviews
    matrix m1 adjuvant - by Bioz Stars, 2026-09
    86/100 stars

    Images

    Related Articles

    other:

    Article Title: A comprehensive overview of vaccines developed for pandemic viral pathogens over the past two decades including those in clinical trials for the current novel SARS-CoV-2
    Article Snippet: ID Vaccine division acronym Vaccine sector description Vaccine category and composition Characteristic nature of vaccination Producers Clinical phases Vaccine utility for other viruses Ref. 8 PS Protein subunit SARS-CoV-2 rS/ Matrix M1adjuvant (full size recombinant SARS CoV-2 GP nanoparticle based vaccine with Matrix Mas adjuvant) Matrix-M, an adjuvant which improves the immune response and induces advanced neutralizing antibodies Novavax Phase 3 NCT04611802, NCT04583995 Ebola, Lassa, MERS, Nipah, Ri Valley Fever and Chikungunya 107 9 RNA RNA based vaccine Moderna mRNA1273 vaccine, LNP encapsulated cell bank; mRNA, VAX (nonreplicating viral vector) A vaccine with mRNA encapsulated in LNP, encoding for perfusion stabilized spike (S) protein.

    Adjuvant:

    Article Title: The quest for a better fight: How can nanomaterials address the current therapeutic and diagnostic obstacles in the fight against COVID-19?
    Article Snippet: Matrix M adjuvant is the Novavax patent, which is more tolerable than the primary formulation and can recruit APCs to the injection site and facilitate antigen presentation in local lymph nodes. .. In 2017, Novavax reported a MERS-CoV S NP vaccine, which was used with Matrix M1 adjuvant in mice [ ]. ..

    Article Title: Systematic Development and Validation of a Bradford-Based Protein Quantification Method for Novel Multi-Dose R21 Malaria Vaccine Formulated with 2-Phenoxy Ethanol (2-PE)
    Article Snippet: .. Matrix M1 adjuvant was obtained from Novavax (Gaithersburg, MD, USA). .. ELISA plates (Nunc MaxiSorp flat bottom), SDS-PAGE molecular weight markers, and the micro BCA protein assay kit were procured from Thermo Fisher Scientific (Waltham, MA, USA).

    Article Title: Systematic Development and Validation of a Bradford-Based Protein Quantification Method for Novel Multi-Dose R21 Malaria Vaccine Formulated with 2-Phenoxy Ethanol (2-PE).
    Article Snippet: .. Matrix M1 adjuvant was obtained from Novavax (Gaithersburg, MD, USA). .. ELISA plates (Nunc MaxiSorp flat bottom), SDS-PAGE molecular weight markers, and the micro BCA protein assay kit were procured from Thermo Fisher Scientific (Waltham, MA, USA).

    Article Title: Comprehensive Highlights of the Universal Efforts towards the Development of COVID-19 Vaccine
    Article Snippet: Twenty-four subunit vaccines, such as those developed by Anhui Zhifei Longcom Biopharmaceutical, Novavax, Sanofi/GlaxoSmithKline (GSK), and Kentucky Bioprocessing, have reached clinical trials, while 68 more vaccine possibilities are undergoing preclinical evaluation. .. Novavax developed NVX-CoV2373, a nanoparticle-based S-protein recombinant vaccine with the Matrix M1 adjuvant containing saponin. ..

    Article Title: Systematic Development and Validation of a Bradford-Based Protein Quantification Method for Novel Multi-Dose R21 Malaria Vaccine Formulated with 2-Phenoxy Ethanol (2-PE).
    Article Snippet: .. We are thankful to the Novavax Team for the supply of Matrix M1 adjuvant for our vaccine. ..

    Article Title: A comparison between SARS-CoV-1 and SARS-CoV2: an update on current COVID-19 vaccines
    Article Snippet: COVIran Barakat (Shifa Pharmed Industrial Co.) [ ] , - Inactivated SARS-CoV-2 virus + alum - Multiple viral antigens , - Double-dose (Day 0 and 14) - IM , - Two different doses (3 μg or 5 μg per dose) evoke a high level of SARS-CoV-2 specific neutralizing antibodies in mice, rabbits, guinea pig, monkeys, and Rhesus macaques on day 21 and day 42 after the first dose , - Required temperature: 2-8°C (refrigerator) , - Common side effects: injection site pain and itch. .. NVX-CoV2373 (Novavax) [ , , , , ] , - Protein subunit full-length recombinant SARS CoV-2 glycoprotein nanoparticle vaccine adjuvant with matrix M1 - Recombinant S protein , -Double-dose (Day 0 and 21) - SARS-CoV-2rS (5 μg) + matrix-M1 adjuvant (50 μg) (co-formulated) - IM , - High levels of S-specific neutralizing (anti-spike IgG antibodies), antibodies prevent the upper respiratory tract infections - It also caused the spleen to produce CD4+ and CD8+ multifunctional T cells, CD4+ follicular T helper cells, and antigen-specific germline B cells , Phase I-II: - Safe - Inducing T helper 1 response - After a second dose of NVX-CoV2373, 100% of participants developed neutralization titers - There was no variation in antibody reaction between 25 μg and 5 μg levels - Two shots had a boosting effect - Required temperature: 2-8°C (refrigerator) - It is a ready-to-use liquid formulation - Efficacy: 95.6% 89.3% (UK), 60.1% (in HIV negative subjects, South Africa) - 60% effective against variant B.1.351 and 85.6% effective against variant B.1.1.7. , - No serious adverse events were observed except mild fever for a day in one receiver - No or mild local adverse events - Efficacy in UK was 89% but it was only 49% in South Africa. .. QazCovid-in®-vaccine (Research Institute for Biological Safety Problems) [ ] , - Inactivated SARS-CoV-2 virus , - Double-dose (Day 0 and 21) - IM , - No published data is available yet , - Immune response is directed against spike protein and many other SARS-CoV-2 antigens - Easy handling - Less expensive - More stable than live attenuated vaccines - Required temperature: 2- 8°C (refrigerator) - 100% Efficacy in phase I - 96% Efficacy in phase II , - Short duration of immune memory (unpublished work) - Common side effects: injection site pain and itch, hyperemia (unpublished work).

    Mouse Assay:

    Article Title: The quest for a better fight: How can nanomaterials address the current therapeutic and diagnostic obstacles in the fight against COVID-19?
    Article Snippet: Matrix M adjuvant is the Novavax patent, which is more tolerable than the primary formulation and can recruit APCs to the injection site and facilitate antigen presentation in local lymph nodes. .. In 2017, Novavax reported a MERS-CoV S NP vaccine, which was used with Matrix M1 adjuvant in mice [ ]. ..

    Recombinant:

    Article Title: Comprehensive Highlights of the Universal Efforts towards the Development of COVID-19 Vaccine
    Article Snippet: Twenty-four subunit vaccines, such as those developed by Anhui Zhifei Longcom Biopharmaceutical, Novavax, Sanofi/GlaxoSmithKline (GSK), and Kentucky Bioprocessing, have reached clinical trials, while 68 more vaccine possibilities are undergoing preclinical evaluation. .. Novavax developed NVX-CoV2373, a nanoparticle-based S-protein recombinant vaccine with the Matrix M1 adjuvant containing saponin. ..

    Article Title: A comparison between SARS-CoV-1 and SARS-CoV2: an update on current COVID-19 vaccines
    Article Snippet: COVIran Barakat (Shifa Pharmed Industrial Co.) [ ] , - Inactivated SARS-CoV-2 virus + alum - Multiple viral antigens , - Double-dose (Day 0 and 14) - IM , - Two different doses (3 μg or 5 μg per dose) evoke a high level of SARS-CoV-2 specific neutralizing antibodies in mice, rabbits, guinea pig, monkeys, and Rhesus macaques on day 21 and day 42 after the first dose , - Required temperature: 2-8°C (refrigerator) , - Common side effects: injection site pain and itch. .. NVX-CoV2373 (Novavax) [ , , , , ] , - Protein subunit full-length recombinant SARS CoV-2 glycoprotein nanoparticle vaccine adjuvant with matrix M1 - Recombinant S protein , -Double-dose (Day 0 and 21) - SARS-CoV-2rS (5 μg) + matrix-M1 adjuvant (50 μg) (co-formulated) - IM , - High levels of S-specific neutralizing (anti-spike IgG antibodies), antibodies prevent the upper respiratory tract infections - It also caused the spleen to produce CD4+ and CD8+ multifunctional T cells, CD4+ follicular T helper cells, and antigen-specific germline B cells , Phase I-II: - Safe - Inducing T helper 1 response - After a second dose of NVX-CoV2373, 100% of participants developed neutralization titers - There was no variation in antibody reaction between 25 μg and 5 μg levels - Two shots had a boosting effect - Required temperature: 2-8°C (refrigerator) - It is a ready-to-use liquid formulation - Efficacy: 95.6% 89.3% (UK), 60.1% (in HIV negative subjects, South Africa) - 60% effective against variant B.1.351 and 85.6% effective against variant B.1.1.7. , - No serious adverse events were observed except mild fever for a day in one receiver - No or mild local adverse events - Efficacy in UK was 89% but it was only 49% in South Africa. .. QazCovid-in®-vaccine (Research Institute for Biological Safety Problems) [ ] , - Inactivated SARS-CoV-2 virus , - Double-dose (Day 0 and 21) - IM , - No published data is available yet , - Immune response is directed against spike protein and many other SARS-CoV-2 antigens - Easy handling - Less expensive - More stable than live attenuated vaccines - Required temperature: 2- 8°C (refrigerator) - 100% Efficacy in phase I - 96% Efficacy in phase II , - Short duration of immune memory (unpublished work) - Common side effects: injection site pain and itch, hyperemia (unpublished work).

    Neutralization:

    Article Title: A comparison between SARS-CoV-1 and SARS-CoV2: an update on current COVID-19 vaccines
    Article Snippet: COVIran Barakat (Shifa Pharmed Industrial Co.) [ ] , - Inactivated SARS-CoV-2 virus + alum - Multiple viral antigens , - Double-dose (Day 0 and 14) - IM , - Two different doses (3 μg or 5 μg per dose) evoke a high level of SARS-CoV-2 specific neutralizing antibodies in mice, rabbits, guinea pig, monkeys, and Rhesus macaques on day 21 and day 42 after the first dose , - Required temperature: 2-8°C (refrigerator) , - Common side effects: injection site pain and itch. .. NVX-CoV2373 (Novavax) [ , , , , ] , - Protein subunit full-length recombinant SARS CoV-2 glycoprotein nanoparticle vaccine adjuvant with matrix M1 - Recombinant S protein , -Double-dose (Day 0 and 21) - SARS-CoV-2rS (5 μg) + matrix-M1 adjuvant (50 μg) (co-formulated) - IM , - High levels of S-specific neutralizing (anti-spike IgG antibodies), antibodies prevent the upper respiratory tract infections - It also caused the spleen to produce CD4+ and CD8+ multifunctional T cells, CD4+ follicular T helper cells, and antigen-specific germline B cells , Phase I-II: - Safe - Inducing T helper 1 response - After a second dose of NVX-CoV2373, 100% of participants developed neutralization titers - There was no variation in antibody reaction between 25 μg and 5 μg levels - Two shots had a boosting effect - Required temperature: 2-8°C (refrigerator) - It is a ready-to-use liquid formulation - Efficacy: 95.6% 89.3% (UK), 60.1% (in HIV negative subjects, South Africa) - 60% effective against variant B.1.351 and 85.6% effective against variant B.1.1.7. , - No serious adverse events were observed except mild fever for a day in one receiver - No or mild local adverse events - Efficacy in UK was 89% but it was only 49% in South Africa. .. QazCovid-in®-vaccine (Research Institute for Biological Safety Problems) [ ] , - Inactivated SARS-CoV-2 virus , - Double-dose (Day 0 and 21) - IM , - No published data is available yet , - Immune response is directed against spike protein and many other SARS-CoV-2 antigens - Easy handling - Less expensive - More stable than live attenuated vaccines - Required temperature: 2- 8°C (refrigerator) - 100% Efficacy in phase I - 96% Efficacy in phase II , - Short duration of immune memory (unpublished work) - Common side effects: injection site pain and itch, hyperemia (unpublished work).

    Formulation:

    Article Title: A comparison between SARS-CoV-1 and SARS-CoV2: an update on current COVID-19 vaccines
    Article Snippet: COVIran Barakat (Shifa Pharmed Industrial Co.) [ ] , - Inactivated SARS-CoV-2 virus + alum - Multiple viral antigens , - Double-dose (Day 0 and 14) - IM , - Two different doses (3 μg or 5 μg per dose) evoke a high level of SARS-CoV-2 specific neutralizing antibodies in mice, rabbits, guinea pig, monkeys, and Rhesus macaques on day 21 and day 42 after the first dose , - Required temperature: 2-8°C (refrigerator) , - Common side effects: injection site pain and itch. .. NVX-CoV2373 (Novavax) [ , , , , ] , - Protein subunit full-length recombinant SARS CoV-2 glycoprotein nanoparticle vaccine adjuvant with matrix M1 - Recombinant S protein , -Double-dose (Day 0 and 21) - SARS-CoV-2rS (5 μg) + matrix-M1 adjuvant (50 μg) (co-formulated) - IM , - High levels of S-specific neutralizing (anti-spike IgG antibodies), antibodies prevent the upper respiratory tract infections - It also caused the spleen to produce CD4+ and CD8+ multifunctional T cells, CD4+ follicular T helper cells, and antigen-specific germline B cells , Phase I-II: - Safe - Inducing T helper 1 response - After a second dose of NVX-CoV2373, 100% of participants developed neutralization titers - There was no variation in antibody reaction between 25 μg and 5 μg levels - Two shots had a boosting effect - Required temperature: 2-8°C (refrigerator) - It is a ready-to-use liquid formulation - Efficacy: 95.6% 89.3% (UK), 60.1% (in HIV negative subjects, South Africa) - 60% effective against variant B.1.351 and 85.6% effective against variant B.1.1.7. , - No serious adverse events were observed except mild fever for a day in one receiver - No or mild local adverse events - Efficacy in UK was 89% but it was only 49% in South Africa. .. QazCovid-in®-vaccine (Research Institute for Biological Safety Problems) [ ] , - Inactivated SARS-CoV-2 virus , - Double-dose (Day 0 and 21) - IM , - No published data is available yet , - Immune response is directed against spike protein and many other SARS-CoV-2 antigens - Easy handling - Less expensive - More stable than live attenuated vaccines - Required temperature: 2- 8°C (refrigerator) - 100% Efficacy in phase I - 96% Efficacy in phase II , - Short duration of immune memory (unpublished work) - Common side effects: injection site pain and itch, hyperemia (unpublished work).

    Variant Assay:

    Article Title: A comparison between SARS-CoV-1 and SARS-CoV2: an update on current COVID-19 vaccines
    Article Snippet: COVIran Barakat (Shifa Pharmed Industrial Co.) [ ] , - Inactivated SARS-CoV-2 virus + alum - Multiple viral antigens , - Double-dose (Day 0 and 14) - IM , - Two different doses (3 μg or 5 μg per dose) evoke a high level of SARS-CoV-2 specific neutralizing antibodies in mice, rabbits, guinea pig, monkeys, and Rhesus macaques on day 21 and day 42 after the first dose , - Required temperature: 2-8°C (refrigerator) , - Common side effects: injection site pain and itch. .. NVX-CoV2373 (Novavax) [ , , , , ] , - Protein subunit full-length recombinant SARS CoV-2 glycoprotein nanoparticle vaccine adjuvant with matrix M1 - Recombinant S protein , -Double-dose (Day 0 and 21) - SARS-CoV-2rS (5 μg) + matrix-M1 adjuvant (50 μg) (co-formulated) - IM , - High levels of S-specific neutralizing (anti-spike IgG antibodies), antibodies prevent the upper respiratory tract infections - It also caused the spleen to produce CD4+ and CD8+ multifunctional T cells, CD4+ follicular T helper cells, and antigen-specific germline B cells , Phase I-II: - Safe - Inducing T helper 1 response - After a second dose of NVX-CoV2373, 100% of participants developed neutralization titers - There was no variation in antibody reaction between 25 μg and 5 μg levels - Two shots had a boosting effect - Required temperature: 2-8°C (refrigerator) - It is a ready-to-use liquid formulation - Efficacy: 95.6% 89.3% (UK), 60.1% (in HIV negative subjects, South Africa) - 60% effective against variant B.1.351 and 85.6% effective against variant B.1.1.7. , - No serious adverse events were observed except mild fever for a day in one receiver - No or mild local adverse events - Efficacy in UK was 89% but it was only 49% in South Africa. .. QazCovid-in®-vaccine (Research Institute for Biological Safety Problems) [ ] , - Inactivated SARS-CoV-2 virus , - Double-dose (Day 0 and 21) - IM , - No published data is available yet , - Immune response is directed against spike protein and many other SARS-CoV-2 antigens - Easy handling - Less expensive - More stable than live attenuated vaccines - Required temperature: 2- 8°C (refrigerator) - 100% Efficacy in phase I - 96% Efficacy in phase II , - Short duration of immune memory (unpublished work) - Common side effects: injection site pain and itch, hyperemia (unpublished work).



    Similar Products

    matrix m1 adjuvant  (Novavax Inc)
    86
    Novavax Inc matrix m1 adjuvant
    Matrix M1 Adjuvant, supplied by Novavax Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/matrix+m1+adjuvant/adjuvant+m+matrix/pm41600941-63-0-6
    Average 86 stars, based on 1 article reviews
    matrix m1 adjuvant - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    adjuvant matrix m1  (Novavax Inc)
    86
    Novavax Inc adjuvant matrix m1
    Adjuvant Matrix M1, supplied by Novavax Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/matrix+m1+adjuvant/adjuvant+m+matrix/pm41176969-66-19-21
    Average 86 stars, based on 1 article reviews
    adjuvant matrix m1 - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    baculovirus-sf9-produced nanoparticle vaccines comprising viral glycoproteins, with and without matrix-m1 or aluminum adjuvants  (Novavax Inc)
    90
    Novavax Inc baculovirus-sf9-produced nanoparticle vaccines comprising viral glycoproteins, with and without matrix-m1 or aluminum adjuvants
    Baculovirus Sf9 Produced Nanoparticle Vaccines Comprising Viral Glycoproteins, With And Without Matrix M1 Or Aluminum Adjuvants, supplied by Novavax Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/matrix+m1+adjuvant/baculovirus+sf9+produced+nanoparticle+vaccines/pmc10536880__NIHMS1927823___supplement___Supplement_2_Trial_Protocol_and_Statistical_Analysis_Plan-771-23-13
    Average 90 stars, based on 1 article reviews
    baculovirus-sf9-produced nanoparticle vaccines comprising viral glycoproteins, with and without matrix-m1 or aluminum adjuvants - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    matrix-m1 adjuvant  (Novavax Inc)
    90
    Novavax Inc matrix-m1 adjuvant
    Matrix M1 Adjuvant, supplied by Novavax Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/matrix+m1+adjuvant/matrix+m+adjuvant/pmc10536880__NIHMS1927823___supplement___Supplement_2_Trial_Protocol_and_Statistical_Analysis_Plan-674-44-8
    Average 90 stars, based on 1 article reviews
    matrix-m1 adjuvant - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    recombinant quadrivalent nanoparticle influenza vaccine matrix-m1™ adjuvant  (Novavax Inc)
    90
    Novavax Inc recombinant quadrivalent nanoparticle influenza vaccine matrix-m1™ adjuvant
    Clinical trials of protein subunit influenza vaccines (including A/H1N1pdm09 strain).
    Recombinant Quadrivalent Nanoparticle Influenza Vaccine Matrix M1™ Adjuvant, supplied by Novavax Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/matrix+m1+adjuvant/recombinant+quadrivalent+nanoparticle+influenza+vaccine+matrix+m1++adjuvant/pmc11621219-21-20-59
    Average 90 stars, based on 1 article reviews
    recombinant quadrivalent nanoparticle influenza vaccine matrix-m1™ adjuvant - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    sars-cov-2 rs/matrix m1-adjuvant  (Novavax Inc)
    90
    Novavax Inc sars-cov-2 rs/matrix m1-adjuvant
    Clinical trials of protein subunit influenza vaccines (including A/H1N1pdm09 strain).
    Sars Cov 2 Rs/Matrix M1 Adjuvant, supplied by Novavax Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/matrix+m1+adjuvant/sars+cov+2+rs+matrix+m1+adjuvant/pmc11170481-44-7-25
    Average 90 stars, based on 1 article reviews
    sars-cov-2 rs/matrix m1-adjuvant - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    sars-cov-2 rs/matrix-m1 adjuvant  (Novavax Inc)
    90
    Novavax Inc sars-cov-2 rs/matrix-m1 adjuvant
    Clinical trials of protein subunit influenza vaccines (including A/H1N1pdm09 strain).
    Sars Cov 2 Rs/Matrix M1 Adjuvant, supplied by Novavax Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/matrix+m1+adjuvant/sars+cov+2+rs+matrix+m1+adjuvant/pmc10879169-50-3-21
    Average 90 stars, based on 1 article reviews
    sars-cov-2 rs/matrix-m1 adjuvant - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Clinical trials of protein subunit influenza vaccines (including A/H1N1pdm09 strain).

    Journal: Frontiers in Immunology

    Article Title: Advances in protein subunit vaccines against H1N1/09 influenza

    doi: 10.3389/fimmu.2024.1499754

    Figure Lengend Snippet: Clinical trials of protein subunit influenza vaccines (including A/H1N1pdm09 strain).

    Article Snippet: A Phase 3, Randomized, Observer-blinded, Active-controlled Trial to Evaluate Immunogenicity & Safety of a Recombinant Quadrivalent Nanoparticle Influenza Vaccine With Matrix-M1™ Adjuvant Against Fluzone® Quadrivalent in Clinically Stable Adults ≥ 65 Years of Age , Allocation: randomized | Intervention model: parallel | Masking: quadruple | Primary purpose: prevention , Biological: NanoFlu Biological: Fluzone Quadrivalent , NCT04120194 , III , Novavax.

    Techniques: Vaccines, Recombinant, Adjuvant, Saline, Virus, Produced, Cell Culture